期刊文献+

体腔热灌注顺铂治疗恶性体腔积液的临床观察 被引量:5

Clinical Efficacy of Thermic Perfusion of Cisplatin in Treatment of Malignant Effusion
下载PDF
导出
摘要 目的:观察体外循环热灌注化疗治疗恶性胸腹水的疗效及不良反应。方法:选择恶性胸腹水患者100例,按照随机数字表法分为治疗组及对照组。治疗组患者50例,采用HGGZ-102体腔循环热化疗系统行体腔热疗,腔内温度达41—43℃,给予顺铂50mg、地塞米松10mg注入体腔,体腔循环持续60min;对照组患者50例,给予体腔注入顺铂50mg。2组患者均进行1周2次的治疗,疗程为2周。结果:治疗组患者总有效率为76.0%(38/50);对照组为46.O%(23/50),治疗组明显优于对照组(P〈0.05);2组不良反应发生率相当。结论:体腔循环灌注热化疗治疗恶性胸腹水疗效好,不良反应可以耐受。 OBJECTIVE:To evaluate the efficacy and side effects of extracorporeal circulation hyperthermic perfusion chemotherapy for malignant pleural effusion or ascites. METHODS: 100 cases of malignant pleural effusion or ascites were randomized to either treatment group or control group of 50 cases each. The treatment group received thermotherapy using HGGZ-102 body cavity circulating thermochemotherapy system with intra-cavity maintained at 41- 43 ℃ circulation maintained for 60 min and into the cavity cisplatin (50 mg) and dexamethasone (10 mg) were injected; while the control group were injected with cisplatin (50 mg) via body cavity. The medications were given twice a week for two consecutive weeks. RESULTS: The response rate in the treatment group was significantly higher than in the control group [ 76.0% ( 38/50 ) vs. 46.0% (23/50) ; P 〈 0.05 ) ; there was no statistically significant difference between the two groups in terms of the incidence of adverse reactions. CONCLUSIONS: Body cavity circumfusion thermochemotherapy is effective for malignant pleural effusion or ascites with tolerable adverse reactions.
出处 《中国医院用药评价与分析》 2014年第10期870-872,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 2011年广东省云浮市科技计划项目(编号:WS 1114)
关键词 恶性胸腹水 热灌注化疗 顺铂 Malignant pleural effusion or ascites Hyperthermic perfusion chemotherapy Cisplatin
  • 相关文献

参考文献12

二级参考文献41

共引文献203

同被引文献50

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部